NEWS
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three objective responses were noted, including one complete response, and the treatment was generally well-tolerated. The company has selected an 18 mg dose of WTX-124 monotherapy for expansion and opened three new trial arms. Additionally, WTX-124 showed enhanced immune activation in combination with pembrolizumab. A webcast to discuss these findings will be held on June 3, 2024.
06/01/2024 - 09:00 AM
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -
- Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response -
- Monotherapy recommended dose for expansion selected and expansion arms open for enrollment -
- Preliminary data on WTX-124 administered to patients in combination with pembrolizumab showed that the combination was generally well-tolerated with enhanced immune activation in tumors -
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy -
- Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response -
- Monotherapy recommended dose for expansion selected and expansion arms open for enrollment -
- Preliminary data on WTX-124 administered to patients in combination with pembrolizumab showed that the combination was generally well-tolerated with enhanced immune activation in tumors -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1165Followers
73Following
8115Visitors
Follow